Bayer presented the long-term studies of Xarelto in patients with coronary artery disease and/or peripheral artery disease.
Bayer has presented the long-term data of the COMPASS trial and the XATOA registry, in which Xarelto (rivaroxaban) plus aspirin showed long-term benefits in patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD). The XATOA registry showed benefits with dual pathway inhibition (DPI).
Bayer, in its statement, mentioned that the Phase III COMPASS study was the largest clinical study of Xarelto. In patients with chronic coronary artery disease and/or peripheral artery disease, Xarelto plus aspirin reduced the risk of stroke, cardiovascular death, and heart attack by 24%.
The LTOLE part of the COMPASS study 3-year data demonstrated that Xarelto 2.5 mg twice daily and aspirin 100 mg once daily resulted in less or the same number of adverse cardiovascular events during the randomized treatment phase.
Xarelto was able to generate revenues of $5.0 billion in 2021.